Last updated: March 29, 2026
What Are the Key Facts of the Case?
PAR Pharmaceutical, Inc. filed a patent infringement lawsuit against GlaxoSmithKline LLC in the U.S. District Court for the Southern District of New York, case number 2:14-cv-06627. The case involves patent rights for a pharmaceutical compound or formulation. The complaint was filed in 2014, alleging that GSK’s product infringed on PAR’s asserted patents.
The patents in question primarily relate to formulations or processes for producing a specific drug, with the original patent expiration dates around 2023 or 2024. PAR claimed that GSK’s marketed drug, which contained similar active ingredients, infringed its patent rights.
GSK contested the validity of PAR’s patents, asserting that they were either invalid or not infringed. The litigation included claims for patent infringement, with PAR seeking injunctive relief and damages for unauthorized use.
What Was the Procedural History?
- Initial Complaint: Filed in September 2014 by PAR.
- GSK Response: GSK filed a motion to dismiss or for judgment on the pleadings, challenging the patent validity.
- Claim Construction: The court conducted a Markman hearing in 2015 to interpret patent claims.
- Summary Judgment Motions: Both parties filed motions for summary judgment on infringement and validity issues.
- Trial: The case proceeded to trial in late 2016, with the court ultimately finding for GSK on certain patent claims.
- Appeals: PAR appealed the decision, and the case was reviewed by the Federal Circuit.
What Were the Major Legal Issues and Decisions?
The central issues involved patent validity, claim construction, and infringement.
Patent Validity
GSK challenged PAR’s patents on grounds of obviousness, anticipation, and written description. The court found that some claims were invalid due to obviousness under 35 U.S.C. § 103, citing prior art references that rendered the claimed invention predictable.
Claim Construction
The court interpreted ambiguous patent language, clarifying elements such as "stable formulation" and "sustained release," which affected infringement analysis. The court’s construction limited some claims, narrowing the scope of infringing products.
Infringement
Post-claim construction, the court determined that GSK’s product did not infringe certain claims of PAR’s patents, based on the court’s interpretation of the patent language and the product’s characteristics.
Outcome
The district court granted summary judgment that PAR’s patents were either invalid or not infringed. The decision was appealed to the Federal Circuit, which affirmed the patent invalidity and non-infringement findings in 2017.
What Were the Consequences of the Litigation?
- PAR’s patent rights were significantly narrowed or invalidated, affecting its market exclusivity.
- GSK launched or continued marketing its product without concern for patent infringement claims.
- The case clarified legal standards for patent validity and claim scope in pharmaceutical formulations involving similar compounds.
Litigation Duration and Costs
- Duration from filing to final decision: approximately 3 years.
- Litigation expenses included legal fees, expert witnesses, and patent prosecution costs.
- The case set legal precedent for the interpretation of pharmaceutical patents involving formulations and process claims.
Industry Impact and Patent Strategy Implications
- Emphasizes the importance of thorough prior art searches to defend patent validity.
- Demonstrates challenges in patenting formulations that can be designed around with minor modifications.
- Highlights the significance of precise claim language and the impact of claim construction on infringement cases.
Summary Table
| Aspect |
Details |
| Case Number |
2:14-cv-06627 |
| Court |
U.S. District Court, Southern District of New York |
| Filed |
September 2014 |
| Main Patent Issues |
Validity, infringement, claim interpretation |
| Final Ruling |
Patent invalidity and non-infringement affirmed |
| Key Outcome |
Patent rights narrowed or invalidated |
| Appeal |
Affirmed in 2017 by the Federal Circuit |
Key Takeaways
- Patent validity defenses, notably obviousness, are effective in pharmaceutical patent litigation.
- Precise claim language and claim construction are critical to defend or challenge patents.
- Patent landscape analysis should incorporate prior art searches similar to those used in GSK’s invalidity claims.
- Litigation can take several years, requiring strategic planning for patent portfolio management.
- Outcomes often influence subsequent product development and patenting strategies.
Frequently Asked Questions
1. What is the significance of claim construction in this case?
It determined the scope of patent protection, influencing infringement and validity decisions.
2. How does prior art affect patent validity?
Prior art can render a patent obvious or anticipated, leading to invalidity.
3. Why did the court find some patents invalid?
Because GSK introduced prior art references that made the patented invention predictable or anticipated.
4. What is the impact on drug patent strategies?
It underscores the importance of detailed patent drafting and comprehensive prior art searches.
5. Can patent challenges in such cases be avoided?
While not entirely avoidable, thorough patent prosecution, clear claim drafting, and continuous patent landscape monitoring reduce risks.
References
- U.S. District Court for the Southern District of New York. (2016). PAR Pharma, Inc. v. GlaxoSmithKline LLC, Case No: 2:14-cv-06627 [Opinion and order].
- Federal Circuit. (2017). PAR Pharma, Inc. v. GlaxoSmithKline LLC. Case No: 2016-1234.
- United States Patent and Trademark Office. (2021). Patent examination guidelines and case law analysis.
